Moonlake Immunotherapeutics · NASDAQ:MLTX
Moonlake Immunotherapeutics shareholders
Moonlake Immunotherapeutics on 6ix: holders from US fund reports; insider trades reported in the US. Largest: T. Rowe Price Capital Appreciation Fund, T. Rowe Price Small-Cap Value Fund, Inc. and T. Rowe Price Health Sciences Fund, Inc. Each with its filing.
| Holder | Shares | % of Moonlake Immunotherapeutics | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | 1.61M | new | Jun 30, 2026 | |
| T. Rowe Price Small-Cap Value Fund, Inc. | 919K | new | Jun 30, 2026 | |
| T. Rowe Price Health Sciences Fund, Inc. | 792K | −94,957 | Jun 30, 2026 | |
| JNL/T. Rowe Price Capital Appreciation Fund | 350K | new | Jun 30, 2026 | |
| T. Rowe Price Capital Appreciation Equity ETF | 168K | new | Jun 30, 2026 | |
| BlackRock Health Sciences Opportunities Portfolio | 161K | new | May 29, 2026 | |
| Vy(R) T. Rowe Price Capital Appreciation Portfolio | 160K | new | Jun 30, 2026 | |
| Select Biotechnology Portfolio | 144K | no change | May 31, 2026 | |
| Penn Series Flexibly Managed Fund | 112K | new | Jun 30, 2026 | |
| Nomura Healthcare Fund | 110K | +30,000 | Jun 30, 2026 |